Endogenous NAMPT dampens chemokine expression and apoptotic responses in stressed tubular cells

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1842, Issue 2, 2014, Pages 293-303

  Benito Martin, Alberto ^a   Ucero, Alvaro C ^a   Izquierdo, María Concepción ^a   Santamaria, Beatriz ^b   Picatoste, Belén ^a   Carrasco, Susana ^a   Lorenzo, Oscar ^a   Ruiz Ortega, Marta ^a   Egido, Jesus ^a   Ortiz, Alberto ^c  

^a 28400 Madrid   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

Author keywords

Apoptosis; Diabetes; Inflammation; Kidney; NAMPT

Indexed keywords

DAPORINAD; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RANTES; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL ACTIVITY; CELL DEATH; CELL FUNCTION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME ACTIVITY; IMMUNOHISTOCHEMISTRY; INTERFERON GAMMA RELEASE ASSAY; KIDNEY TUBULE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TARGET CELL;

APOPTOSIS; DIABETES; INFLAMMATION; KIDNEY; NAMPT;

ACRYLAMIDES; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE; CHEMOKINE CCL2; CHEMOKINE CCL5; CHEMOKINES; DIABETES MELLITUS, EXPERIMENTAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; KIDNEY; KIDNEY TUBULES, PROXIMAL; NAD; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PIPERIDINES; RATS; RATS, INBRED WKY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84890844870     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2013.11.022     Document Type: Article

References (54)

1. Engelgau M.M. The evolving diabetes burden in the United States. Ann. Intern. Med. 2004, 140:945-950.
2. Fernandez Fernandez B., Elewa U., Sanchez-Nino M.D., Rojas-Rivera J.E., Martin-Cleary C., Egido J., Ortiz A. 2012 update on diabetic kidney disease: the expanding spectrum, novel pathogenic insights and recent clinical trials. Minerva Med. 2012, 103:219-234.
3. Adeghate Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions. Curr. Med. Chem. 2008, 15:1851-1862.
4. Sanz A.B., Santamaria B., Ruiz-Ortega M., Egido J., Ortiz A. Mechanisms of renal apoptosis in health and disease. J. Am. Soc. Nephrol. 2008, 19:1634-1642.
5. Sanchez-Nino M.D., Benito-Martin A., Ortiz A. New paradigms in cell death in human diabetic nephropathy. Kidney Int. 2010, 78:737-744.
6. Kumar Evidence of apoptosis in human diabetic kidney. Mol. Cell. Biochem. 2004, 259:67-70.
7. Susztak K., Schiffer M., Böttinger E.P. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006, 55:225-233.
8. Sanchez-Nino M.D., Sanz A.B., Lorz C., Gnirke A., Rastaldi M.P., Nair V., Egido J., Ruiz-Ortega M., Kretzler M., Ortiz A. BASP1 promotes apoptosis in diabetic nephropathy. J. Am. Soc. Nephrol. 2010, 21:610-621.
9. Navarro J.F., Mora-Fernandez C. The role of TNF-alpha in diabetic nephropathy: pathogenic and therapeutic implications. Cytokine Growth Factor Rev. 2006, 17:441-450.
10. Lorz C., Benito-Martin A., Boucherot A., Ucero A.C., Rastaldi M.P., Henger A., Armelloni S., Santamaria B., Berthier C.C., Kretzler M., Egido J., Ortiz A. The death ligand TRAIL in diabetic nephropathy. J. Am. Soc. Nephrol. 2008, 19:904-914.
11. Samal B., Sun Y., Stearns G., Xie C., Suggs S., McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol. Cell. Biol. 1994, 14:1431-1437.
12. Fukuhara A., Matsuda M., Nishizawa M., Segawa K., Tanaka M., Kishimoto K., Matsuki Y., Murakami M., Ichisaka T., Murakami H., Watanabe E., Takagi T., Akiyoshi M., Ohtsubo T., Kihara S., Yamashita S., Makishima M., Funahashi T., Yamanaka S., Hiramatsu R., Matsuzawa Y., Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005, 307:426-430.
13. Rongvaux A., Shea R.J., Mulks M.H., Gigot D., Urbain J., Leo O., Andris F. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur. J. Immunol. 2002, 32:3225-3234.
14. Zhang L.Q., Heruth D.P., Ye S.Q. Nicotinamide phosphoribosyltransferase in human diseases. J. Bioanal. Biomed. 2011, 3:13-25.
15. Wang T., Zhang X., Bheda P., Revollo J.R., Imai S., Wolberger C. Structure of Nampt/PBEF/visfatin, a mammalian NAD+ biosynthetic enzyme. Nat. Struct. Mol. Biol. 2006, 13:661-662.
16. Moschen A.R., Geiger S., Gerner R., Tilg H. Pre-B cell colony enhancing factor/NAMPT/visfatin and its role in inflammation-related bone disease. Mutat. Res. 2010, 690:95-101.
17. Liu P., Li H., Cepeda J., Xia Y., Kempf J.A., Ye H., Zhang L.Q., Ye S.Q. Regulation of inflammatory cytokine expression in pulmonary epithelial cells by pre-B-cell colony-enhancing factor via a nonenzymatic and AP-1-dependent mechanism. J. Biol. Chem. 2009, 284:27344-27351.
18. Kim J.Y., Bae Y.H., Bae M.K., Kim S.R., Park H.J., Wee H.J., Bae S.K. Visfatin through STAT3 activation enhances IL-6 expression that promotes endothelial angiogenesis. Biochim. Biophys. Acta 2009, 1793:1759-1767.
19. Wang P., Xu T.Y., Guan Y.F., Su D.F., Fan G.R., Miao C.Y. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Cardiovasc. Res. 2009, 81:370-380.
20. Hasmann M., Schemainda I. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res. 2003, 63:7436-7442.
21. Song H.K., Lee M.H., Kim B.K., Park Y.G., Ko G.J., Kang Y.S., Han J.Y., Han S.Y., Han K.H., Kim H.K., Cha D.R. Visfatin: a new player in mesangial cell physiology and diabetic nephropathy. Am. J. Physiol. Renal Physiol. 2008, 295:F1485-F1494.
22. Kang Y.S., Song H.K., Lee M.H., Ko G.J., Han J.Y., Han S.Y., Han K.H., Kim H.K., Cha D.R. Visfatin is upregulated in type-2 diabetic rats and targets renal cells. Kidney Int. 2010, 78:170-181.
23. Sanchez-Nino M.D., Sanz A.B., Sanchez-Lopez E., Ruiz-Ortega M., Benito-Martin A., Saleem M.A., Mathieson P.W., Mezzano S., Egido J., Ortiz A. HSP27/HSPB1 as an adaptive podocyte antiapoptotic protein activated by high glucose and angiotensin II. Lab. Invest. 2012, 92:32-45.
24. Sanz A.B., Justo P., Sanchez-Nino M.D., Blanco-Colio L.M., Winkles J.A., Kreztler M., Jakubowski A., Blanco J., Egido J., Ruiz-Ortega M., Ortiz A. The cytokine TWEAK modulates renal tubulointerstitial inflammation. J. Am. Soc. Nephrol. 2008, 19:695-703.
25. Ortiz A., Ziyadeh F.N., Neilson E.G. Expression of apoptosis-regulatory genes in renal proximal tubular epithelial cells exposed to high ambient glucose and in diabetic kidneys. J. Investig. Med. 1997, 45:50-56.
26. Li Y., Zhang Y., Dorweiler B., Cui D., Wang T., Woo C.W., Brunkan C.S., Wolberger C., Imai S., Tabas I. Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism. J. Biol. Chem. 2008, 283:34833-34843.
27. Justo P., Sanz A.B., Sanchez-Nino M.D., Winkles J.A., Lorz C., Egido J., Ortiz A. Cytokine cooperation in renal tubular cell injury: the role of TWEAK. Kidney Int. 2006, 70:1750-1758.
28. Santamaria B., Benito-Martin A., Ucero A.C., Aroeira L.S., Reyero A., Vicent M.J., Orzaez M., Celdran A., Esteban J., Selgas R., Ruiz-Ortega M., Cabrera M.L., Egido J., Perez-Paya E., Ortiz A. A nanoconjugate Apaf-1 inhibitor protects mesothelial cells from cytokine-induced injury. PLoS One 2009, 4:e6634.
29. Sanchez-Nino M.D., Sanz A.B., Ihalmo P., Lassila M., Holthofer H., Mezzano S., Aros C., Groop P.H., Saleem M.A., Mathieson P.W., Langham R., Kretzler M., Nair V., Lemley K.V., Nelson R.G., Mervaala E., Mattinzoli D., Rastaldi M.P., Ruiz-Ortega M., Martin-Ventura J.L., Egido J., Ortiz A. The MIF receptor CD74 in diabetic podocyte injury. J. Am. Soc. Nephrol. 2009, 20:353-362.
30. Sanchez-Nino M.D., Bozic M., Cordoba-Lanus E., Valcheva P., Gracia O., Ibarz M., Fernandez E., Navarro-Gonzalez J.F., Ortiz A., Valdivielso J.M. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. Am. J. Physiol. Renal Physiol. 2012, 302:F647-F657.
31. Romacho T., Azcutia V., Vazquez-Bella M., Matesanz N., Cercas E., Nevado J., Carraro R., Rodriguez-Manas L., Sanchez-Ferrer C.F., Peiro C. Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity. Diabetologia 2009, 52:2455-2463.
32. Kang Y.S., Bae M.K., Kim J.Y., Jeong J.W., Yun I., Jang H.O., Bae S.K. Visfatin induces neurite outgrowth in PC12 cells via ERK1/2 signaling pathway. Neurosci. Lett. 2011, 504:121-126.
33. Revollo J.R., Korner A., Mills K.F., Satoh A., Wang T., Garten A., Dasgupta B., Sasaki Y., Wolberger C., Townsend R.R., Milbrandt J., Kiess W., Imai S. Nampt/PBEF/visfatin regulates insulin secretion in beta cells as a systemic NAD biosynthetic enzyme. Cell Metab. 2007, 6:363-375.
34. Retnakaran R., Youn B.S., Liu Y., Hanley A.J., Lee N.S., Park J.W., Song E.S., Vu V., Kim W., Tungtrongchitr R., Havel P.J., Swarbrick M.M., Shaw C., Sweeney G. Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: a cross-sectional study. Clin. Endocrinol. (Oxf) 2008, 69:885-893.
35. Mercader J., Granados N., Caimari A., Oliver P., Bonet M.L., Palou A. Retinol-binding protein 4 and nicotinamide phosphoribosyltransferase/visfatin in rat obesity models. Horm. Metab. Res. 2008, 40:467-472.
36. Mazaki-Tovi S., Romero R., Kusanovic J.P., Vaisbuch E., Erez O., Than N.G., Chaiworapongsa T., Nhan-Chang C.L., Pacora P., Gotsch F., Yeo L., Kim S.K., Edwin S.S., Hassan S.S., Mittal P. Maternal visfatin concentration in normal pregnancy. J. Perinat. Med. 2009, 37:206-217.
37. Lewandowski K.C., Stojanovic N., Press M., Tuck S.M., Szosland K., Bienkiewicz M., Vatish M., Lewinski A., Prelevic G.M., Randeva H.S. Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance. Diabetologia 2007, 50:1033-1037.
38. Carrero J.J., Witasp A., Stenvinkel P., Qureshi A.R., Heimburger O., Barany P., Suliman M.E., Anderstam B., Lindholm B., Nordfors L., Schalling M., Axelsson J. Visfatin is increased in chronic kidney disease patients with poor appetite and correlates negatively with fasting serum amino acids and triglyceride levels. Nephrol. Dial. Transplant. 2010, 25:901-906.
39. Axelsson J., Witasp A., Carrero J.J., Qureshi A.R., Suliman M.E., Heimburger O., Barany P., Lindholm B., Alvestrand A., Schalling M., Nordfors L., Stenvinkel P. Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. Am. J. Kidney Dis. 2007, 49:237-244.
40. Brentano F., Schorr O., Ospelt C., Stanczyk J., Gay R.E., Gay S., Kyburz D. Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities. Arthritis Rheum. 2007, 56:2829-2839.
41. Huang Q., Guo Y., Zeng H., Xie W., Yan H., Ding H. Visfatin stimulates a cellular renin-angiotensin system in cultured rat mesangial cells. Endocr. Res. 2011, 36:93-100.
42. Galli M., Van Gool F., Rongvaux A., Andris F., Leo O. The nicotinamide phosphoribosyltransferase: a molecular link between metabolism, inflammation, and cancer. Cancer Res. 2010, 70:8-11.
43. Van Gool F., Galli M., Gueydan C., Kruys V., Prevot P.P., Bedalov A., Mostoslavsky R., Alt F.W., De Smedt T., Leo O. Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuin-dependent manner. Nat. Med. 2009, 15:206-210.
44. Peiro C., Romacho T., Carraro R., Sanchez-Ferrer C.F. Visfatin/PBEF/Nampt: a new cardiovascular targetα. Front. Pharmacol. 2010, 1:135.
45. Vallejo S., Romacho T., Angulo J., Villalobos L.A., Cercas E., Leivas A., Bermejo E., Carraro R., Sanchez-Ferrer C.F., Peiro C. Visfatin impairs endothelium-dependent relaxation in rat and human mesenteric microvessels through nicotinamide phosphoribosyltransferase activity. PLoS One 2011, 6:e27299.
46. Borradaile N.M., Pickering J.G. Nicotinamide phosphoribosyltransferase imparts human endothelial cells with extended replicative lifespan and enhanced angiogenic capacity in a high glucose environment. Aging Cell 2009, 8:100-112.
47. Yang Y., Fu W., Chen J., Olashaw N., Zhang X., Nicosia S.V., Bhalla K., Bai W. SIRT1 sumoylation regulates its deacetylase activity and cellular response to genotoxic stress. Nat. Cell Biol. 2007, 9:1253-1262.
48. Dan L., Klimenkova O., Klimiankou M., Klusman J.H., van den Heuvel-Eibrink M.M., Reinhardt D., Welte K., Skokowa J. The role of sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells. Haematologica 2012, 97:551-559.
49. Okumura S., Sasaki T., Minami Y., Ohsaki Y. Nicotinamide phosphoribosyltransferase: a potent therapeutic target in non-small cell lung cancer with epidermal growth factor receptor-gene mutation. J. Thorac. Oncol. 2012, 7:49-56.
50. Bi T.Q., Che X.M., Liao X.H., Zhang D.J., Long H.L., Li H.J., Zhao W. Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor FK866 in combination with fluorouracil. Oncol. Rep. 2011, 26:1251-1257.
51. Rongvaux A., Galli M., Denanglaire S., Van Gool F., Dreze P.L., Szpirer C., Bureau F., Andris F., Leo O. Nicotinamide phosphoribosyl transferase/pre-B cell colony-enhancing factor/visfatin is required for lymphocyte development and cellular resistance to genotoxic stress. J. Immunol. 2008, 181:4685-4695.
52. Benito-Martin A., Ucero A.C., Santamaria B., Lorz C., Kretzler M., Rastaldi M.P., Sanchez-Nino M.D., Sanz A., Izquierdo M.C., Ruiz Ortega M., Egido J., Ortiz A. Transcriptomics illustrate a deadly TRAIL to diabetic nephropathy. Nefrologia 2009, 29:13-19.
53. Jacques C., Holzenberger M., Mladenovic Z., Salvat C., Pecchi E., Berenbaum F., Gosset M. Proinflammatory actions of visfatin/nicotinamide phosphoribosyltransferase (Nampt) involve regulation of insulin signaling pathway and Nampt enzymatic activity. J. Biol. Chem. 2012, 287:15100-15108.
54. Burgos E.S. NAMPT in regulated NAD biosynthesis and its pivotal role in human metabolism. Curr. Med. Chem. 2011, 18:1947-1961.